The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Eric Simpson, Robert Bissonnette, Lawrence F. Eichenfield, Emma Guttman-Yassky, Brett King, Jonathan I. Silverberg, Lisa A. Beck, Thomas Bieber, Kristian Reich, Kenji Kabashima, Marieke Seyger, Elaine Siegfried, Georg Stingl, Steven R. Feldman, Alan Menter, Peter van de Kerkhof, Gil Yosipovitch, Carle Paul, Philippe Martel, Ariane Dubost-BramaJohn Armstrong, Rajeev Chavda, Steve Frey, Yolandi Joubert, Marina Milutinovic, Anne Parneix, Henrique D. Teixeira, Chen Yen Lin, Luna Sun, Paul Klekotka, Brian Nickoloff, Yves Dutronc, Lotus Mallbris, Jonathan M. Janes, Amy M. DeLozier, Fabio P. Nunes, Amy S. Paller

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Background: An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization. Objectives: To develop an IGA scale, training module, and clinical certification examination for use in AD trials; establish content validity; and assess reliability. Methods: Expert dermatologists participated in the development of the validated IGA for AD (vIGA-ADTM). Reliability (interrater and intrarater) was assessed by 2 web-based surveys. Clinical certification for investigators consisted of a training module and examination. Results: Expert consensus was achieved around a 5-point IGA scale including morphologic descriptions, and content validity was established. Survey 1 showed strong interrater reliability (Kendall's coefficient of concordance W [Kendall's W], 0.809; intraclass correlation [ICC], 0.817) and excellent agreement (weighted kappa, 0.857). Survey 2, completed 5 months after training of dermatologists, showed improvements in scale reliability (Kendall's W, 0.819; ICC, 0.852; weighted kappa, 0.889). In this study, 627 investigators completed vIGA-AD training and certification. Limitations: Ratings were assessed on photographs. Conclusion: A validated IGA scale and training module were developed with the intent of harmonizing assessment of disease severity in AD trials. Strong reliability and excellent agreement between assessments were observed.

Original languageEnglish (US)
Pages (from-to)839-846
Number of pages8
JournalJournal of the American Academy of Dermatology
Volume83
Issue number3
DOIs
StatePublished - Sep 2020

Keywords

  • Investigator Global Assessment
  • atopic dermatitis
  • atopic eczema
  • clinical outcome measure
  • severity
  • validated

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis'. Together they form a unique fingerprint.

Cite this